Ethical and Clinical Boundaries in Genomics & Newborn Screening: A Brief Report from IPIC2025

Area of Science:

• Medical Ethics
• Genomics
• Public Health

Background:

• Genomic-enhanced newborn screening programs, initially for severe combined immunodeficiency (SCID), are increasingly identifying incidental findings of serious, non-treatable genetic disorders.
• The International Primary Immunodeficiency Congress (IPIC) Ethics Session addressed the complex ethical landscape of these incidental detections.

Purpose of the Study:

• To explore the ethical challenges of incidental findings in genomic-enhanced newborn screening.
• To discuss the implications of early diagnosis for non-treatable conditions, using ataxia-telangiectasia (AT) as a case study.

Main Methods:

• A fictionalized clinical scenario based on recent literature was used to facilitate discussion.
• The session involved an examination of presymptomatic detection, parental consent, and systemic pressures of expanded genomic testing.

Main Results:

• Key ethical issues identified include the clinical utility versus psychological risks of presymptomatic diagnosis.
• Shortcomings in parental consent processes and the management of incidental findings were highlighted.
• Systemic pressures from expanding genomic testing create significant ethical dilemmas.

Conclusions:

• There is a critical need for internationally coordinated frameworks to manage incidental detections in newborn screening.
• Ethical guidelines are essential as genomic technologies become integrated into routine public health practices.